Navigation Links
Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
Date:5/19/2009

;=300 mg/m2 5.6% 2/68 500 mg/m2 15% 2/43 600 mg/m2 32% 0/36 >600 48% 1/25 (1) Cancer 97: 2869, 2003

The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI previously announced that its pivotal phase III (PIX 301) EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission.

Pixantrone recipients had a low incidence of severe neutropenia complicated by either fever or documented infections, or severe vomiting or diarrhea. Pixantrone patients also experienced a low incidence of hair loss, a very common side effect of other drugs in this class. Overall, the incidence of serious adverse events was similar between pixantrone and the control arm. The pixantrone patients had a higher incidence of leucopenia and neutropenia. Disease progression reported as an adverse event was less frequent in the pixantrone than in the control arm (1.5% vs. 13.4%).

CTI will be presenting additional new efficacy and safety data at the u
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
2. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
3. New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
4. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
5. Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
8. Tanning and Excessive Sun Exposure Can Cause Severe Damage to Eyes
9. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
10. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
(Date:3/4/2015)... Lancée par l,Assistance ... en décembre 2011, l,étude collaborative française randomisée ... compare   l es microsphères en résine ... le carcinome hépatocellulaire avancé, a recruté plus de ...   ; les résultats sont attendus fin 2016. ...
(Date:3/3/2015)... WASHINGTON , March 3, 2015 NASA astronaut ... his launch this month to spend a year living and ... live satellite interviews from 5:30 to 7 a.m. EDT Monday, ... Moscow as he completes the final weeks of ... by a video on NASA Television highlighting his mission training ...
(Date:3/3/2015)... 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and Chief Executive Officer of Neurocrine Biosciences, will ... Miami.   The live presentation takes place ... The presentation will be webcast and may be accessed ... Listeners are encouraged to visit the website ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... 16, 2011 Reportlinker.com announces that a new ... Global Growth Factors ( ... http://www.reportlinker.com/p0397766/Global-Growth-Factors--Blood-And-Tissue--Industry.html This report ... And Tissue) in US$ Million by the following ...
... March 16, 2011 Reportlinker.com announces that a ... catalogue: Global Specialty Enzymes Industry ... This report analyzes the worldwide markets for Specialty ... segments - Specialty Medical Enzymes, Polymerases, Nucleases, and ...
... 2011 PharmAthene, Inc. (Amex: PIP ) ... chemical threats, announced today that its financial results for ... released on Monday, March 28, 2011. PharmAthene ... Company,s fourth quarter and year-end financial results.  The call ...
Cached Biology Technology:Global Growth Factors ( Blood And Tissue ) Industry 2Global Growth Factors ( Blood And Tissue ) Industry 3Global Growth Factors ( Blood And Tissue ) Industry 4Global Growth Factors ( Blood And Tissue ) Industry 5Global Growth Factors ( Blood And Tissue ) Industry 6Global Growth Factors ( Blood And Tissue ) Industry 7Global Growth Factors ( Blood And Tissue ) Industry 8Global Growth Factors ( Blood And Tissue ) Industry 9Global Growth Factors ( Blood And Tissue ) Industry 10Global Growth Factors ( Blood And Tissue ) Industry 11Global Growth Factors ( Blood And Tissue ) Industry 12Global Growth Factors ( Blood And Tissue ) Industry 13Global Growth Factors ( Blood And Tissue ) Industry 14Global Growth Factors ( Blood And Tissue ) Industry 15Global Growth Factors ( Blood And Tissue ) Industry 16Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21
(Date:2/5/2015)... 2015  It is gratifying to see that the ... genomic science as a means to better understand human ... I was honored to participate in today,s White House ... Since the 1980s my teams have ... first sequenced genome of a free living organism, the ...
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , ... it will showcase its EyeLock ID technology integrated in a ... Energy,s Oak Ridge National Laboratory (ORNL) at the ... identity authentication technology is being used to validate the driver ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... spinal cord injury is receiving attention in the research ... department of biomedical engineering at NJIT, recently has published ... stimulators for individuals with spinal cord injuries. ... of support from a four-year, $1.4 million National Institutes ...
... Inc. (Nasdaq: AWRE ), a global provider ... of the Next-Generation Universal Automated Booking Station, or "Universal ... of Justice. Universal ABS is a biometric enrollment application ... modular, COTS software framework that is far more easily ...
... S.C., Oct. 17, 2011 Integrated Biometrics, a South ... announced today that they have launched a new FBI ... device has been tested by The MITRE Corporation and ... Certified Product List. Watson is the world,s first non-optical ...
Cached Biology News:NJIT researcher testing micro-electronic stimulators for spinal cord injuries 2Aware Develops Next-Generation Biometric Enrollment Application for Department of Justice 2Aware Develops Next-Generation Biometric Enrollment Application for Department of Justice 3Aware Develops Next-Generation Biometric Enrollment Application for Department of Justice 4The World's First Non Optical FBI Appendix F Certified Fingerprint Sensor 2
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
... C-terminal reactive. Cross-reacts fully with GLP-1(1-36) ... with the unamidated forms GLP-1(7-37) and ... as hGLP-2, glucagon, hGIP and VIP.,SPECIES ... identical in all mammalian species studied ...
Biology Products: